공시 • May 07
Bio-Techne Corporation announces Quarterly dividend, payable on May 29, 2026 Bio-Techne Corporation announced Quarterly dividend of USD 0.0800 per share payable on May 29, 2026, ex-date on May 18, 2026 and record date on May 18, 2026. 공시 • Apr 18
Bio-Techne Corporation Introduces Streamlined Brand Architecture With Three Portfolio Brands Bio-Techne Corporation announced a streamlined brand architecture designed to enable scientists and clinicians to more easily find the answers they need based on their application and stage of research. The company has organized its products and technologies under three focused portfolio brands -- R&D Systems™, Bio-Techne Spatial™, and Bio-Techne Diagnostics™ -- aligning its solutions with the way modern science progresses from early discovery through translational insights to clinical diagnostics. The portfolio brands will debut at the AACR Annual Meeting 2026 and AAI's IMMUNOLOGY 2026™. The R&D Systems portfolio brings together Bio-Techne's trusted proteins, antibodies, immunoassays, small molecules and innovative instruments used by scientists worldwide. R&D Systems solutions help researchers generate reproducible results, validate discoveries, and advance early-stage research towards clinical application with confidence. R&D Systems provides dependable tools needed to explore, experiment, and uncover new biological insights. R&D Systems also provides key GMP-grade reagents and tools essential for advancing cell and gene therapy workflows. The Bio-Techne Spatial portfolio leverages technologies that help researchers and clinicians translate biology and disease context across both the gold-standard RNAscope™ in situ hybridization technology and the automated COMET™ spatial hyperplex platform. Bio-Techne Spatial solutions enable scalable, high-resolution visualization of RNA and protein with multiomic analysis, delivering exceptional sensitivity and precision to reveal differences in cell structure, identify clinically relevant biomarkers, inform pathology-driven research questions and accelerate therapeutic discovery. The Bio-Techne Diagnostics portfolio provides clinical laboratories and IVD manufacturers with assay kits, IVD-grade reagents, antibodies, molecular controls, calibrators, and proficiency-testing materials needed to design, develop, and validate reliable diagnostic assays. The portfolio supports the full lifecycle of assay development from early design through deployment at scale. By delivering high-quality raw materials and comprehensive assay solutions, Bio-Techne Diagnostics helps ensure accuracy, strengthens clinical decision-making, and ultimately contributes to improved patient outcomes. Together, these three portfolios create a clearer, more connected path for customers by providing a streamlined, end-to-end view of Bio-Techne's solutions, aligning tools and technologies from discovery through translation to clinical diagnostics and accelerating scientific and clinical progress. R&D Systems™ now includes the legacy brands Novus Biologicals™, Tocris Bioscience™, and ProteinSimple™; Bio-Techne Spatial now includes the legacy brands Lunaphore™, and Advanced Cell Diagnostics™; Bio-Techne Diagnostics now includes Asuragen®, Bionostics, Cliniqa, RNA Medical®, and R&D Systems™ Clinical Controls. 공시 • Mar 25
Bio-Techne Corporation Expands Comet Solution Portfolio with Addition of Spyre Focus Panels and Spyre Amplification Kits Bio-Techne Corporation announced the expansion of its COMET solution portfolio with the addition of the new SPYRE Focus Panels and SPYRE Amplification Kits. Together, these strengthen the COMET technology modular, automated spatial biology workflow, delivering expanded flexibility, greater sensitivity, and enabling deeper, more focused interrogation of biologically meaningful data from initial assay design through final interpretation. To support these updates, new features of HORIZON Image Analysis Software have also been introduced, tailored for COMET hyperplex images using the new SPYRE tools, further streamlining tissue analysis. SPYRE Antibody Panels, including the newly introduced Stroma and Vessel Focused Panels, are modular antibody panels designed to enable flexible multiplex assay design while reducing optimization time. Panels leverage validated antibodies with ready-to-use protocols to streamline setup while maintaining flexibility to incorporate markers from a lab's own antibody library. SPYRE Amplification Kits use seqLA technology to improve the detection of low-abundance and difficult-to-detect targets. Together, SPYRE Focus Panels and SPYRE Amplification Kits strengthen Bio-Techne's commitment to deliver a fully integrated, modular, and automated spatial biology ecosystem that accelerates research and preclinical therapeutic development. These innovations continue to empower researchers to generate richer data and deeper biological understanding from every tissue sample. 공시 • Feb 16
Bio-Techne's Ella Platform Achieves Ce-Ivd Marking Expanding Access to Rapid, Cartridge-Based Immunoassays for European Clinical Laboratories Bio-Techne Corporation announced that the Ella benchtop immunoassay platform has received CE-IVD marking and is now available for sale in the European Union. This achievement brings Ella's hallmark ease of use, speed and reproducibility to clinical settings, helping laboratories streamline workflows and support timely decision-making. Ella is a compact, cartridge-based immunoassay system that delivers accurate biomarker results in under 90 minutes with minimal hands-on time. By simplifying the manual steps of traditional immunoassays, Ella reduces operator variability and provides high-quality, reproducible data suitable for both translational research and clinical applications. The platform is compatible with Simple Plex™? assays, which remain for research use only, and are powered by R&D Systems antibodies and proteins. With more than 390 analytes across neuroscience, immunology, oncology, and cell and gene therapy, the Simple Plex portfolio enables researchers to maintain consistency and data quality while working efficiently across a wide range of applications. With CE-IVD marking now in place, hospitals, clinical laboratories, or other European organizations may use Ella as a validated platform for in-house test development, clinical trials, or other translational activities. Diagnostic assay developers may also develop clinical applications on the Ella CE-IVD validated platform. The certification enhances confidence in Ella's performance and supports Bio-Techne's long-term goal to advance precision medicine by providing dependable, standardized solutions for biomarker detection. 공시 • Feb 11
Bio-Techne Corporation Announces Executive Changes, Effective March 1, 2026 Bio-Techne Corporation announced that Dr. Matt McManus, President of Bio-Techne's Diagnostics and Spatial Biology Segment, will be transitioning from his role, effective March 1, 2026, and will remain with Bio-Techne for a period of time to support a smooth transition. Steve Crouse, currently Senior Vice President of Bio-Techne's Analytical Solutions Division, has been appointed President, Diagnostics and Spatial Biology Segment, effective March 1, 2026. Steve has over two decades of experience as a senior life sciences leader at various companies. As Senior Vice President, Analytical Solutions Division, he is responsible for Bio-Techne's portfolio of protein analysis instruments and immunoassays and has driven strategic initiatives, successfully launched several innovative platforms and delivered strong growth during his four-year tenure. Before joining Bio-Techne, he most recently served as General Manager of Thermo Fisher Scientific's Protein Detection and Quantification business unit. He has an MBA from the Marshall School of Business at the University of Southern California and a M.S. in Biochemistry from Georgetown University. 공시 • Feb 04
Bio-Techne Corporation Declares Dividend for the Quarter Ended December 31, 2025, Payable on February 27, 2026 Bio-Techne Corporation announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended December 31, 2025. The quarterly dividend will be payable February 27, 2026, to all common shareholders of record on February 16, 2026. 
